Journal profile · Respiratory System
Tuberculosis
ISSN 1472-9792 · eISSN 1873-281X · Churchill Livingstone · ENGLAND · Bimonthly · Founded 2001
Tuberculosis: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 2.22; hybrid open access; APC about USD 2,690; median 102 days to acceptance (96 articles, last 24 months); community-reported acceptance: moderate; 88 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Tuberculosis is published by Churchill Livingstone and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Tuberculosis Research and Epidemiology, Mycobacterium research and diagnosis and Diagnosis and treatment of tuberculosis, together about 63.3% of its articles. Its main subfields are Epidemiology. (generated from OpenAlex topic counts and CAS ranking data)
Tuberculosis is a speciality journal focusing on basic experimental research on tuberculosis.Tuberculosis aims to publish original research and reviews. It publishes articles on host response and immunology of tuberculosis and the molecular biology, genetics and physiology of the organism.Submissions on bacteriological, immunological and pathogenesis aspects of the disease are particularly welcomed.The journal publishes topics including:• Clinical Trials • Diagnostics • Antimicrobial resistance • Immunology • Leprosy • Microbiology, including microbial physiology • Molecular epidemiology • Non-tuberculous Mycobacteria • Pathogenesis & Pathology • Vaccine developmentPlease note Tuberculosis does not consider:submissions with a meta-analytical focus (e.g., articles based on searches of published articles in public electronic databases will not be considered, especially where there is lack of evidence of the personal involvement of authors in the generation of such material). articles reporting the reanalysis of published data sets to generate hypotheses where there is lack of evidence of the personal involvement of authors in the generation of such material, and where no attempt has been made to test hypotheses experimentally will not be considered.case report submissions or clinical case studies. Submit manuscripts of this type to the companion journals IDCases and Clinical Microbiology Newsletter.articles reporting in silico drug discovery and molecular modelling will not be considered without experimental work to demonstrate meaningful insight into the activity of the series under investigation; further biological evaluation of the mechanism of action, cytotoxicity and potential for drug development is encouraged.Review articles that do NOT offer novel perspectives or insight into a topic and are NOT of general interest to the readership of the journal, or have been covered recently elsewhere, will not be considered.
From the journal's Aims & Scope
Research area (LetPub): Respiratory System
Editor-in-chief Brian RobertsonPublisher website
Editorial board by country: 4 in mainland China (about 17%); most named United Kingdom 6, United States 5, Mainland China 4, Sweden 2, Japan 1 (24 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Tuberculosis Research and EpidemiologyMedicine35.9%
- Mycobacterium research and diagnosisMedicine19.1%
- Diagnosis and treatment of tuberculosisMedicine8.3%
- Infectious Diseases and TuberculosisMedicine7.3%
- Pneumocystis jirovecii pneumonia detection and treatmentMedicine3.8%
- Immunodeficiency and Autoimmune DisordersImmunology and Microbiology2.4%
- Pneumonia and Respiratory InfectionsMedicine2.4%
- Diverse Scientific and Economic StudiesEconomics, Econometrics and Finance2.1%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Immunology | Zone 4 |
| Minor | Microbiology | Zone 4 |
| Minor | Respiratory System | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Immunology | Zone 4 |
| Minor | Microbiology | Zone 4 |
| Minor | Respiratory System | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Microbiology | Zone 3 |
| Minor | Immunology | Zone 4 |
| Minor | Respiratory System | Zone 4 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 2.22LetPub ·
- Impact factor (publisher)
- 2.9Publisher website ·
- CiteScore 2026-06
- 4.3LetPub ·
- CiteScore (publisher)
- 4.3Publisher website ·
- SJR 2026-06
- 0.67LetPub ·
- SNIP 2026-06
- 0.8LetPub ·
- h-index
- 79LetPub ·
- h-index
- 111OpenAlex ·
- i10-index
- 1,622OpenAlex ·
- 2-year mean citedness
- 2.44OpenAlex ·
- Self-citation rate
- 3.4%LetPub ·
- Share of gold OA articles
- 27.39%LetPub ·
Volume
- Articles per year
- 67LetPub ·
Articles by year OpenAlex count · 3,645 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 54 | 21 | 14 |
| 2025 | 88 | 28 | 155 |
| 2024 | 88 | 41 | 393 |
| 2023 | 112 | 58 | 713 |
| 2022 | 115 | 51 | 1,073 |
| 2021 | 76 | 19 | 1,144 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
102 daysMedian, submission to acceptance · P25–P75 75 days – 132 days
- Acceptance to online
- median 1 days (96 articles)
- Submission to online
- median 105 days
- Sample
- 96 articles with submission and acceptance dates (156 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 1 monthLetPub ·
- Average acceptance (community reports)
- ModerateLetPub ·
- Submission to first decision
- 5 daysPublisher website ·
- First decision after review
- 46 daysPublisher website ·
- Submission to acceptance
- 106 daysPublisher website ·
- Acceptance to publication
- 2 daysPublisher website ·
- Peer review
- Single anonymous peer reviewPublisher website
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 2,690 / EUR 2,520 / GBP 2,150 / JPY 333,640 | — | — | |
| Publisher website | USD 2,980 | — | — |
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Article types accepted10, with length limits
- commentsComments: Editorial comments are generally invited by the Tuberculosis Editorial team. They are 1,500 words in length with no abstract or keywords .Length not stated
- editorialOriginal Articles: The form of these articles is discussed fully below under manuscript preparation; an abstract is required.Letters: Headings should not be use…Length not stated
- letterOriginal Articles: The form of these articles is discussed fully below under manuscript preparation; an abstract is required.Letters: Headings should not be use…Length not stated
- lettersLetters: Headings should not be used in a letter; no abstract or keywords are required. The text should be no more than 800 words; there should be a maximum of …Length not stated
- original articleOriginal Articles: The form of these articles is discussed fully below under manuscript preparation; an abstract is required.Letters: Headings should not be use…Length not stated
- original articlesOriginal Articles: The form of these articles is discussed fully below under manuscript preparation; an abstract is required.Length not stated
- reviewOriginal Articles: The form of these articles is discussed fully below under manuscript preparation; an abstract is required.Letters: Headings should not be use…Length not stated
- reviewsReviews: An abstract and keywords are required. The text should be divided into sections by suitable headings. Tables and figures may be used as appropriate for…Length not stated
- short communicationOriginal Articles: The form of these articles is discussed fully below under manuscript preparation; an abstract is required.Letters: Headings should not be use…main text ≤ 2,500 words
- short communicationsShort Communications: These should be no more than 2,500 words, with up to 15 references and a maximum of 3 figures or tables.Length not stated
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, Publication ethics, License & copyright, Open access, Peer review, Preprints
- AI use Declaration of generative AI use
Authors must declare the use of generative AI tools in the manuscript preparation process upon submission of the paper.Generative AI and AI-assisted technologies (“AI tools”) have been rapidly adopted in research and scholarly publishing, offering significant benefits while requiring clear standards for responsible and transparent use.Authors preparing a manuscript for this journal may use AI tool…
Source ↗Publisher website ·- Authorship Group authorship
Group authorship refers to the attribution of an article to a defined and named group of authors whose members have contributed to the work. Examples include research consortia, clinical trial groups, collaborative networks, task forces or working groups, expert panels or consensus groups, and participatory research groups. Group authorship must be declared on the title page at submission. When av…
Source ↗Publisher website ·- Conflicts of interest Declaration of competing interests
All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence or bias their work. Examples of potential competing interests include:EmploymentConsultanciesStock ownershipHonorariaPaid expert testimonyPatent applications or registrationsGrants or any other fundingAffiliation with the journal as an Editor or Advisory Board …
Source ↗Publisher website ·- Publication ethics
Authors must follow ethical guidelines stated in Elsevier's Publishing Ethics Policy. Model summary
Authors must follow ethical guidelines stated in Elsevier's Publishing Ethics Policy.
Source ↗Publisher website ·- License & copyright License options
Authors will be offered open access user license options which will determine how you, and third parties, can reuse your open access article. We advise that you review these options and any funding body license requirements before selecting a license option.
Source ↗Publisher website ·- Open access Open access
We refer you to our open access information page to learn about open access options for this journal.
Source ↗Publisher website ·- Peer review Peer review
Single anonymized review process; submissions initially assessed by editors; if suitable, sent to a minimum of two reviewers; decision made by editors. Model summary
This journal follows a single anonymized review process. Your submission will initially be assessed by our editors. If your submission is deemed suitable, it will typically be sent to be reviewed by a minimum of two reviewers for an independent expert assessment of the scientific quality. The decision as to whether your article is accepted or rejected for publication will be made by our editors.Re…
Source ↗Publisher website ·- Preprints Preprints
Preprint sharing is allowed in line with Elsevier's article sharing policy; sharing preprints will not count as prior publication. Model summary
Preprint sharingAuthors may share preprints in line with Elsevier's article sharing policy. Sharing preprints, such as on a preprint server, will not count as prior publication.We advise you to read our policy on multiple, redundant or concurrent publication. In support of Open Science, this journal offers its authors a free preprint posting service on SSRN, Elsevier’s preprint and early research …
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Churchill Livingstone
- Country or region
- ENGLAND
- Language
- English
- Frequency
- Bimonthly
- Founded
- 2001
- ISSN
- 1472-9792
- Electronic ISSN
- 1873-281X
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗Publisher website
- Special issues ↗Publisher website
FAQ
Frequently asked questions about Tuberculosis
What CAS zone is Tuberculosis in?
In the 2025 upgraded edition of the CAS Journal Ranking, Tuberculosis is in Zone 4 of Medicine, and in Zone 4 of the minor category Immunology / Microbiology / Respiratory System. In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Tuberculosis?
The latest impact factor listed by LetPub is 2.22; CiteScore 4.3, h-index 111.
How long does peer review take at Tuberculosis?
Based on the dates recorded on 96 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 102 days (interquartile range 75–132 days); authors report an average review time of about 1 month; the community-reported acceptance is “Moderate”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Where are the editorial board members of Tuberculosis based?
Of the 24 board members whose country the journal's board page names, 4 (about 17%) are in mainland China; the countries named most often are United Kingdom (6), United States (5) and Mainland China (4). Counted from the institutions listed on the board page; for reference only.
Which databases index Tuberculosis?
According to LetPub and DOAJ records, Tuberculosis is indexed in SCIE and Scopus.
Is Tuberculosis open access, and what is the APC?
Tuberculosis is a hybrid journal. For open-access publication: APC about USD 2,690.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .